Suzhou Yasheng Pharmaceutical Co., Ltd Report issue

For profit Phase 2

Organization Overview

First Clinical Trial
2020
NCT04501120
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Suzhou Yasheng Pharmaceutical Co., Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

apg2575 (1 trial)

azacitidine (vidaza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2